OS Therapies Incorporated
AMEX:OSTXBiotechnology
+$0.10 today
- Market cap
- $53.83M
- Beta
- -0.95
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$0.91
Volume 0.50M
Average 0.71M
OSTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
OS Therapies IncorporatedAMEX: OSTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $10.4M (cash outflow) rose 168.2% year over year, behind the +254398.4% change in trailing-twelve-month net income. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at +1562.8% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$20.38M (-99.9%) for the fiscal year ending Dec 2026, a slowdown from the +323597.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.4M-100.0% QoQ
- Last fiscal yearDec 2025
- -$28.75B+323597.5% YoY
- LTMMar 2026
- -$28.76B+254398.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +168.2% | +32.1% | -136.0 pp |
| 1 year | +323597.5% | -99.9% | -323697.4 pp |
| 3-year CAGR | +1562.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (28.75B) USD
- Year-over-year change
- -323597.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (28.75B) | -323597.5% |
| FY2024 | 2024-12-31 | (8.88M) | -14.0% |
| FY2023 | 2023-12-31 | (7.79M) | -24.6% |
| FY2022 | 2022-12-31 | (6.25M) | +15.7% |
| FY2021 | 2021-12-31 | (7.42M) | — |
Net Income vs competitors
How OSTX compares with its peers on the latest reported figures
- OSTX's LTM Mar 2026 net income of $28.76B is the largest of the 9 companies compared; the peer median is $33.23M.
- Its year-over-year change of +254398.4% is the highest of 8, against a peer median of +1.8%.
- Over three fiscal years its annual growth of +1562.8% compares with a peer median of -17.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $28.76B | +254398.4% | +1562.8% | — |
| LTM Mar 2026 | $12.49B | +128201.2% | -23.6% | — | |
| LTM Mar 2026 | $60.96M | -388.6% | -1.9% | 18297.5% | |
| LTM Mar 2026 | $37.19M | -32.9% | -5.5% | — | |
| LTM Jun 2026 | $34.61M | -52.7% | +4.2% | 164.8% | |
| LTM Jun 2024 | $31.85M | — | -39.6% | 3904.3% | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $19.06M | +36.2% | -28.9% | — | |
| LTM Mar 2026 | $12.72M | +12.6% | -31.8% | 899.5% | |
| Peer median (excluding OSTX) | $33.23M | +1.8% | -17.0% | 1070.2% | |
Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75B) |
| Depreciation & Amortization | 805 | 805 | 4.22K | 2.78K | 363.09M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 268.3K | 4.27B |
| Change in Working Capital | 574.67K | 947.33K | 2.02M | (129.64K) | 9.11M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 856.48K | 216.43K | 1.35M | (1.05M) | 8.27M |
| Other Working Capital | (281.81K) | 730.9K | 669.65K | 923.69K | 834.81K |
| Other Non-Cash Items | 2.44M | 1.51M | 2.76M | 1.46M | 9.88B |
| Operating Cash Flow | (4.4M) | (3.79M) | (3.01M) | (7.28M) | (14.24B) |
| Capital Expenditures | (11.93K) | 0 | 0 | 0 | (466.42K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 212.41K | 230.88K | 1.15K | 0 | (465.96M) |
| Investing Cash Flow | 200.47K | 230.88K | 1.15K | 0 | (466.42M) |
| Debt Repayment | 2.95M | 3.82M | 3.16M | 1.5M | 0 |
| Common Stock Issued | 0 | 0 | 0 | 5.23M | 8.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (31.25M) | 0 |
| Other Financing Activities | 100K | (172.02K) | (284.18K) | 31.25M | 9.43B |
| Financing Cash Flow | 3.05M | 3.65M | 2.87M | 12.78M | 9.44B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.15M) | 90.69K | (132.5K) | 5.49M | (5.26B) |
| Free Cash Flow | (4.41M) | (3.79M) | (3.01M) | (7.28M) | (14.24B) |
OS Therapies Incorporated
AMEX:OSTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.